Does kisqali cause hair thinning?

What causes hair thinning with Kisqali?

Kisqali contains ribociclib, a CDK4/6 inhibitor used for hormone receptor-positive breast cancer. Hair thinning is listed as a possible side effect in the prescribing information. Patients commonly report it as a mild to moderate effect that occurs during treatment.

Does it affect everyone?

The rate of hair thinning varies among patients. Some experience noticeable thinning, some mild shedding, and some report no change at all. Incidence rates are drawn from clinical trials and differ by combination therapy, whether with endocrine therapy or letrozole alone.

How does it compare to similar drugs?

Kisqali, Ibrance, and Verzenio all belong to the CDK4/6 inhibitor class. Hair thinning occurs across the entire class. The degree of severity varies between drugs and between patients. Many patients find it manageable with scalp care routines or wig options.

When does hair thinning start and does es it recover?

Hair thinning starts typically during the first few months of treatment. After stopping Kisqali, hair regrows in most cases. Regrowth occurs slower than original hair, sometimes with changes in texture or color.

Are there ways to manage it?

Patients use cold caps, topical minoxidil, gentle shampoos, and proper nutrition to keep hair strong. These strategies do not guarantee prevention or recovery. They help many patients keep their hair during treatment.

What happens if the thinning becomes severe?

Severe thinning or alopecia areata-like patterns occur in rare cases. If this occurs, patients discuss dose interruption or reduction with their oncologist.